Publications by authors named "M Prasanna Kumar"

Background: Out-of-pocket expenditure (OOPE) and catastrophic health expenditure (CHE) on institutional deliveries in India impose significant financial burdens, disproportionately affecting socio-economically vulnerable populations and regions despite various policy interventions.

Purpose: This study evaluates the extent of OOPE and CHE associated with institutional deliveries across Indian states and analyse regional variations using data from National Family Health Survey -5 (2019-21).

Results: The findings reveal substantial inter-state and regional disparities in mean OOPE and CHE incidence, with socioeconomic and healthcare system factors significantly influencing these outcomes.

View Article and Find Full Text PDF

Bacterial diseases alone or in combination with other pathogens lead to significant economic losses in poultry globally including India. One of these diseases is avian colibacillosis which is caused by avian pathogenic Escherichia coli (APEC). The present study sought to isolate and characterize using in vivo and in vitro assays E.

View Article and Find Full Text PDF

The pathophysiology of dystonia in Wilson disease (WD) is complex and poorly understood. Copper accumulation in the basal ganglia, disrupts dopaminergic pathways, contributing to dystonia's development via neurotransmitter imbalance. Despite advances in diagnosis and management, WD with dystonia remains a challenging condition to treat.

View Article and Find Full Text PDF

Background: Parkinson's disease (PD) is characterized by dopaminergic (DA) neuron loss, Lewy body build-up, and motor dysfunction. One of the primary pathogenic mechanisms of PD development is autophagy dysfunction and nitric oxide-mediated neurotoxicity.

Purpose: The current study focuses on autophagy and nitric oxide (NO) signaling roles in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated PD mice and their protection by their modulators.

View Article and Find Full Text PDF

Tyrosine kinase inhibitors have been employed for the treatment of lung cancer, owing to their role in regulating irregulated pathways or mutated genes. Bosutinib, a nonreceptor tyrosine kinase, has been recently investigated for lung cancer treatment. Bosutinib can also be used with paclitaxel as a combinatorial approach to receive a synergistic effect for the effective management of lung cancer.

View Article and Find Full Text PDF